FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W50472604> ?p ?o ?g. }

• W50472604 endingPage "12" @default.
• W50472604 startingPage "1" @default.
• W50472604 abstract "In the PROTECT AF (Watchman Left Atrial Appendage Closure Technology for Embolic Protection in Patients With Atrial Fibrillation) trial that evaluated patients with nonvalvular atrial fibrillation (NVAF), left atrial appendage (LAA) occlusion was noninferior to warfarin for stroke prevention, but a periprocedural safety hazard was identified.The goal of this study was to assess the safety and efficacy of LAA occlusion for stroke prevention in patients with NVAF compared with long-term warfarin therapy.This randomized trial further assessed the efficacy and safety of the Watchman device. Patients with NVAF who had a CHADS2 (congestive heart failure, hypertension, age >75 years, diabetes mellitus, and previous stroke/transient ischemic attack) score ≥2 or 1 and another risk factor were eligible. Patients were randomly assigned (in a 2:1 ratio) to undergo LAA occlusion and subsequent discontinuation of warfarin (intervention group, n = 269) or receive chronic warfarin therapy (control group, n = 138). Two efficacy and 1 safety coprimary endpoints were assessed.At 18 months, the rate of the first coprimary efficacy endpoint (composite of stroke, systemic embolism [SE], and cardiovascular/unexplained death) was 0.064 in the device group versus 0.063 in the control group (rate ratio 1.07 [95% credible interval (CrI): 0.57 to 1.89]) and did not achieve the prespecified criteria noninferiority (upper boundary of 95% CrI ≥1.75). The rate for the second coprimary efficacy endpoint (stroke or SE >7 days' postrandomization) was 0.0253 versus 0.0200 (risk difference 0.0053 [95% CrI: -0.0190 to 0.0273]), achieving noninferiority. Early safety events occurred in 2.2% of the Watchman arm, significantly lower than in PROTECT AF, satisfying the pre-specified safety performance goal. Using a broader, more inclusive definition of adverse effects, these still were lower in PREVAIL (Watchman LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy) trial than in PROTECT AF (4.2% vs. 8.7%; p = 0.004). Pericardial effusions requiring surgical repair decreased from 1.6% to 0.4% (p = 0.027), and those requiring pericardiocentesis decreased from 2.9% to 1.5% (p = 0.36), although the number of events was small.In this trial, LAA occlusion was noninferior to warfarin for ischemic stroke prevention or SE >7 days' post-procedure. Although noninferiority was not achieved for overall efficacy, event rates were low and numerically comparable in both arms. Procedural safety has significantly improved. This trial provides additional data that LAA occlusion is a reasonable alternative to warfarin therapy for stroke prevention in patients with NVAF who do not have an absolute contraindication to short-term warfarin therapy." @default.
• W50472604 created "2016-06-24" @default.
• W50472604 creator A5004967840 @default.
• W50472604 creator A5019177993 @default.
• W50472604 creator A5032182838 @default.
• W50472604 creator A5049607555 @default.
• W50472604 creator A5062893992 @default.
• W50472604 creator A5063097243 @default.
• W50472604 creator A5069820090 @default.
• W50472604 creator A5084185852 @default.
• W50472604 date "2014-07-01" @default.
• W50472604 modified "2023-10-14" @default.
• W50472604 title "Prospective Randomized Evaluation of the Watchman Left Atrial Appendage Closure Device in Patients With Atrial Fibrillation Versus Long-Term Warfarin Therapy" @default.
• W50472604 cites W1277893079 @default.
• W50472604 cites W1999468381 @default.
• W50472604 cites W2053482681 @default.
• W50472604 cites W2071154986 @default.
• W50472604 cites W2084936492 @default.
• W50472604 cites W2097854437 @default.
• W50472604 cites W2101863341 @default.
• W50472604 cites W2102464096 @default.
• W50472604 cites W2106947867 @default.
• W50472604 cites W2107050765 @default.
• W50472604 cites W2111395084 @default.
• W50472604 cites W2113089341 @default.
• W50472604 cites W2114775432 @default.
• W50472604 cites W2115996784 @default.
• W50472604 cites W2117244124 @default.
• W50472604 cites W2125627053 @default.
• W50472604 cites W2126789285 @default.
• W50472604 cites W2127211051 @default.
• W50472604 cites W2127884497 @default.
• W50472604 cites W2135694398 @default.
• W50472604 cites W2136489990 @default.
• W50472604 cites W2137434301 @default.
• W50472604 cites W2149388786 @default.
• W50472604 cites W2159193915 @default.
• W50472604 cites W2165920611 @default.
• W50472604 cites W2166503147 @default.
• W50472604 cites W2335777565 @default.
• W50472604 cites W2435343268 @default.
• W50472604 cites W4362054082 @default.
• W50472604 doi "https://doi.org/10.1016/j.jacc.2014.04.029" @default.
• W50472604 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24998121" @default.
• W50472604 hasPublicationYear "2014" @default.
• W50472604 type Work @default.
• W50472604 sameAs 50472604 @default.
• W50472604 citedByCount "1264" @default.
• W50472604 countsByYear W504726042014 @default.
• W50472604 countsByYear W504726042015 @default.
• W50472604 countsByYear W504726042016 @default.
• W50472604 countsByYear W504726042017 @default.
• W50472604 countsByYear W504726042018 @default.
• W50472604 countsByYear W504726042019 @default.
• W50472604 countsByYear W504726042020 @default.
• W50472604 countsByYear W504726042021 @default.
• W50472604 countsByYear W504726042022 @default.
• W50472604 countsByYear W504726042023 @default.
• W50472604 crossrefType "journal-article" @default.
• W50472604 hasAuthorship W50472604A5004967840 @default.
• W50472604 hasAuthorship W50472604A5019177993 @default.
• W50472604 hasAuthorship W50472604A5032182838 @default.
• W50472604 hasAuthorship W50472604A5049607555 @default.
• W50472604 hasAuthorship W50472604A5062893992 @default.
• W50472604 hasAuthorship W50472604A5063097243 @default.
• W50472604 hasAuthorship W50472604A5069820090 @default.
• W50472604 hasAuthorship W50472604A5084185852 @default.
• W50472604 hasBestOaLocation W504726041 @default.
• W50472604 hasConcept C126322002 @default.
• W50472604 hasConcept C127413603 @default.
• W50472604 hasConcept C164705383 @default.
• W50472604 hasConcept C168563851 @default.
• W50472604 hasConcept C203092338 @default.
• W50472604 hasConcept C207103383 @default.
• W50472604 hasConcept C2775914520 @default.
• W50472604 hasConcept C2776301958 @default.
• W50472604 hasConcept C2778715236 @default.
• W50472604 hasConcept C2779161974 @default.
• W50472604 hasConcept C2780434050 @default.
• W50472604 hasConcept C2780645631 @default.
• W50472604 hasConcept C2910272107 @default.
• W50472604 hasConcept C44249647 @default.
• W50472604 hasConcept C71924100 @default.
• W50472604 hasConcept C78519656 @default.
• W50472604 hasConceptScore W50472604C126322002 @default.
• W50472604 hasConceptScore W50472604C127413603 @default.
• W50472604 hasConceptScore W50472604C164705383 @default.
• W50472604 hasConceptScore W50472604C168563851 @default.
• W50472604 hasConceptScore W50472604C203092338 @default.
• W50472604 hasConceptScore W50472604C207103383 @default.
• W50472604 hasConceptScore W50472604C2775914520 @default.
• W50472604 hasConceptScore W50472604C2776301958 @default.
• W50472604 hasConceptScore W50472604C2778715236 @default.
• W50472604 hasConceptScore W50472604C2779161974 @default.
• W50472604 hasConceptScore W50472604C2780434050 @default.
• W50472604 hasConceptScore W50472604C2780645631 @default.
• W50472604 hasConceptScore W50472604C2910272107 @default.
• W50472604 hasConceptScore W50472604C44249647 @default.

• next